Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
54 pending office actions • 33 art units • 54 examiners • 1 of 54 (2%) have an AI response strategy ready • 70 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 15 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 15 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 3 (6%) |
| §101 + other | 10 (19%) |
| §103 only | 12 (22%) |
| §102 only | 4 (7%) |
| §112 only | 3 (6%) |
| Double-patenting + other | 3 (6%) |
| Multi-statute (no §101) | 19 (35%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REMALY, MARK DONALD | 1 | 70.5% | +15.9% |
| KO, TONY | 1 | 87.8% | +2.6% |
| GANGLE, BRIAN J | 1 | 76.7% | +14.7% |
| TRAN, ANH Q | 1 | 90.2% | +4.9% |
| FERNANDEZ, KATHERINE L | 1 | 57.9% | +38.1% |
| NAKHJAVAN, SHERVIN K | 1 | 88.3% | +11.1% |
| TEHRANI, DANIEL | 1 | 59.0% | +42.3% |
| NG, JONATHAN K | 1 | 35.6% | +13.4% |
| LUONG, PETER | 1 | 69.0% | +26.4% |
| NGUYEN, AMANDA DANG | 1 | — | — |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18887555 | PERSONALIZED PROFILING OF FUTURE BRAIN TRAJECTORIES AND FUTURE DISEASE EVOLUTION USING GENERATIVE ARTIFICIAL INTELLIGENCE | NAKHJAVAN, SHERVIN K | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18184497 | ORGANIC PHOTOSENSITIVE DEVICES WITH EXCITON-BLOCKING CHARGE CARRIER FILTERS | CHERN, CHRISTINA | 85d overdue |
| 17399920 | CLASSIFICATION OF SUBTYPES OF KIDNEY TUMORS USING DNA METHYLATION | GOLDBERG, JEANINE ANNE | 42d overdue |
| 18934954 | PHYSIOLOGICAL METRICS FOR DETERMINING STROKE RISK | FERNANDEZ, KATHERINE L | 36d overdue |
| 18401817 | THIN FILM ENDOVASCULAR ELECTRODE ARRAY AND METHOD OF FABRICATION | PREMRAJ, CATHERINE C | 14d |
| 18618449 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES | BAKSHI, PANCHAM | 42d |
| 17928690 | METHODS AND COMPOSITIONS FOR IN VITRO AFFINITY MATURATION OF MONOCLONAL ANTIBODIES | BUNKER, AMY M | 63d |
| 18554917 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | ALAWADI, SARAH | 70d |
| 17794920 | COMPOSITIONS AND METHODS TO TREAT NEUROLOGICAL DISEASES | GIBBS, TERRA C | 72d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18833524 | IDENTIFYING NON-DISEASE PATIENTS USING A DISEASE RELATED ASSAY AND ANALYSIS IN THE LIQUID BIOPSY | NG, JONATHAN K | 85d overdue |
| 18934954 | PHYSIOLOGICAL METRICS FOR DETERMINING STROKE RISK | FERNANDEZ, KATHERINE L | 36d overdue |
| 19164913 | AIRWAY EXCHANGE BRONCHOSCOPE CONSTRUCTION | REMALY, MARK DONALD | — |
| 18962908 | FASTING-MIMICKING DIET (FMD) BUT NOT WATER-ONLY FASTING PROMOTES REVERSAL OF INFLAMMATION AND IBD PATHOLOGY | GANGLE, BRIAN J | — |
| 18887555 | PERSONALIZED PROFILING OF FUTURE BRAIN TRAJECTORIES AND FUTURE DISEASE EVOLUTION USING GENERATIVE ARTIFICIAL INTELLIGENCE | NAKHJAVAN, SHERVIN K | — |
| 18818488 | TRANSCUTANEOUS ELECTRICAL SPINAL CORD NEUROMODULATOR AND USES THEREOF | TEHRANI, DANIEL | — |
| 18734823 | METHOD AND SYSTEM FOR OBSERVING BRAIN STATES WITH FUNCTIONAL ULTRASOUND IMAGING AND A SONOLUCENT INTERFACE | LUONG, PETER | — |
| Art Unit | Apps |
|---|---|
| 1658 | 3 |
| 1682 | 3 |
| 3798 | 2 |
| 3792 | 2 |
| 3619 | 2 |
| 1617 | 2 |
| 1635 | 2 |
| 1693 | 2 |
| 1618 | 2 |
| 3797 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19164913 | AIRWAY EXCHANGE BRONCHOSCOPE CONSTRUCTION | REMALY, MARK DONALD | 3797 | §102§103 | Non-Final OA | — | Pending | Sep 12, 2025 |
| 19079287 | COHERENT DETECTION FOR THE IDENTIFICATION OF SCATTERED LASER LIGHT IN A BRIGHT INCOHERENT BACKGROUND | KO, TONY | — | §101§102§112 | Non-Final OA | — | Pending | Mar 13, 2025 |
| 18962908 | FASTING-MIMICKING DIET (FMD) BUT NOT WATER-ONLY FASTING PROMOTES REVERSAL OF INFLAMMATION AND IBD PATHOLOGY | GANGLE, BRIAN J | — | §102 | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18866501 | High-Speed Compact Look-Up Table with Input Select and Registers | TRAN, ANH Q | 2844 | §102§103 | Non-Final OA | — | Pending | Nov 15, 2024 |
| 18934954 | PHYSIOLOGICAL METRICS FOR DETERMINING STROKE RISK | FERNANDEZ, KATHERINE L | 3798 | §103§112 | Final Rejection | 36d overdue | Pending | Nov 01, 2024 |
| 18887555 | PERSONALIZED PROFILING OF FUTURE BRAIN TRAJECTORIES AND FUTURE DISEASE EVOLUTION USING GENERATIVE ARTIFICIAL INTELLIGENCE | NAKHJAVAN, SHERVIN K | — | §103 | Non-Final OA | — | Pending | Sep 17, 2024 |
| 18818488 | TRANSCUTANEOUS ELECTRICAL SPINAL CORD NEUROMODULATOR AND USES THEREOF | TEHRANI, DANIEL | 3792 | §103§112 | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18833524 | IDENTIFYING NON-DISEASE PATIENTS USING A DISEASE RELATED ASSAY AND ANALYSIS IN THE LIQUID BIOPSY | NG, JONATHAN K | 3619 | §103 | Final Rejection | 85d overdue | Pending | Jul 26, 2024 |
| 18734823 | METHOD AND SYSTEM FOR OBSERVING BRAIN STATES WITH FUNCTIONAL ULTRASOUND IMAGING AND A SONOLUCENT INTERFACE | LUONG, PETER | — | §102§103 | Non-Final OA | — | Pending | Jun 05, 2024 |
| 18714060 | SCHEDULING DISTRIBUTED COMPUTING BASED ON COMPUTATIONAL AND NETWORK ARCHITECTURE | NGUYEN, AMANDA DANG | — | §101§102§103§112 | Non-Final OA | — | Pending | May 28, 2024 |
| 18703290 | DIRECT HYDROGENATION OF METAL CARBONATE AND RELATED SALTS TO METHANOL, METHANE AND METAL HYDROXIDE | WITHERSPOON, SIKARL A | — | §102§103 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18702327 | COMPOSITE PREPREG CONSTRUCTIONS AND METHODS FOR MAKING THE SAME | DAGENAIS, KRISTEN A | 1781 | §103 | Non-Final OA | — | Pending | Apr 17, 2024 |
| 18625740 | HUMAN CEREBELLAR ORGANOIDS WITH BONA FIDE PURKINJE CELLS AND USES THEREOF | SMALL, KATHERINE R | — | §112 | Non-Final OA | — | Pending | Apr 03, 2024 |
| 18618449 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES | BAKSHI, PANCHAM | 1623 | §101Other | Final Rejection | 42d | Pending | Mar 27, 2024 |
| 18689693 | MIXED SOLVENT HYDROGEL SYSTEM FOR WOUND HEALING | CONIGLIO, AUDREA JUNE BUCKLEY | 1617 | §103 | Non-Final OA | 33d | Pending | Mar 06, 2024 |
| 18682656 | SYSTEMS AND METHODS FOR IMPROVED SECURE AGGREGATION IN FEDERATED LEARNING | HOOVER, BRENT JOHNSTON | — | §101§102§103§112 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18430372 | BACKSIDE OPTICAL COUPLER | MOONEY, MICHAEL P | 2874 | §102 | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18580889 | GENETICALLY ENGINEERED MULTIFUNCTIONAL EXOSOMES FOR IMMUNOTHERAPY | NICKOL, GARY B | — | §102§112DP | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18402685 | SYSTEMS AND METHODS TO ACCELERATE GEL-SOL TRANSITION FOR THERMORESPONSIVE HYDROGELS | AZPURU, CARLOS A | 1617 | §102§103 | Non-Final OA | — | Pending | Jan 02, 2024 |
| 18401817 | THIN FILM ENDOVASCULAR ELECTRODE ARRAY AND METHOD OF FABRICATION | PREMRAJ, CATHERINE C | 3794 | §102§103 | Final Rejection | 14d | Pending | Jan 02, 2024 |
| 18573421 | MONOLITHIC PERICARDIAL PACEMAKERS | EDWARDS, PHILIP CHARLES | 3792 | §103 | Final Rejection | — | Pending | Dec 21, 2023 |
| 18571407 | AUGMENTED MEMORY COMPUTING: A NEW PATHWAY FOR EFFICIENT AI COMPUTATIONS | CHO, SUNG IL | 2825 | §103 | Final Rejection | 50d overdue | Pending | Dec 18, 2023 |
| 18565306 | NOVEL THERAPEUTIC PEPTIDES FOR NEURODEGENERATION | MIDDLETON, DANAYA L | 1674 | §101§112 | Non-Final OA | — | Pending | Nov 29, 2023 |
| 18561889 | CHIMERIC ANTIGEN RECEPTOR-MODIFIED GRANULOCYTE-MACROPHAGE PROGENITORS FOR CANCER IMMUNOTHERAPY | WESTON, ALYSSA G | 1633 | §102§103§112Other | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18561900 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | CORDAS, EMILY ANN | 1632 | §102§103DP | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18558275 | SYSTEMS AND METHODS FOR IDENTIFYING NOVEL PORE-FORMING TOXINS | TOMASZEWSKI, MICHAEL | — | §101 | Non-Final OA | — | Pending | Oct 31, 2023 |
| 18385174 | CD70-TARGETED MICELLES ENHANCE HIF2a siRNA DELIVERY AND INHIBIT ONCOGENIC FUNCTIONS IN PATIENT-DERIVED CLEAR CELL RENAL CARCINOMA CELLS | KONOPKA, CATHERINE ANNE | 1635 | §102§103§112 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18493223 | THERAPEUTIC POLY-ADP-RIBOSE POLYMER-GCSF CONJUGATES | LAU, JONATHAN S | 1693 | §102§103§112 | Non-Final OA | — | Pending | Oct 24, 2023 |
| 18380447 | CONVERSION OF WASTE PLASTICS TO HIGH-VALUE METABOLITES | HAUK TEODORO, PRICILA NMN | 1645 | §102§103 | Non-Final OA | — | Pending | Oct 16, 2023 |
| 18554917 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | ALAWADI, SARAH | 1619 | §102§103Other | Final Rejection | 70d | Pending | Oct 11, 2023 |
| 18376040 | MIXED-KERNEL HETEROJUNCTION TRANSISTORS, FABRICATING METHODS, AND APPLICATIONS OF THE SAME | KIM, SU C | 2899 | §102 | Non-Final OA | — | Pending | Oct 03, 2023 |
| 18285227 | COMPOSITIONS AND METHODS FOR MODULTING INFLAMMATORY AND DEGENERATIVE DISORDER | LEE, JIA-HAI | 1658 | §101§102§103DP | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18546472 | CELL-FREE DNA METHYLATION TEST | JONES, CHRISTINE MICHELLE | 1682 | §101§102§103§112 | Non-Final OA | — | Pending | Aug 15, 2023 |
| 18449154 | HIGHLY SENSITIVE AND SPECIFIC LUCIFERASE BASED REPORTER ASSAY FOR ANTIGEN DETECTION | HAQ, SHAFIQUL | 1678 | §103 | Non-Final OA | — | Pending | Aug 14, 2023 |
| 18263582 | ENZYME INHIBITORS AND VIRAL INFECTION THERAPY | VAJDA, KRISTIN ANN | 1622 | §102§112 | Non-Final OA | — | Pending | Jul 31, 2023 |
| 18210978 | FLUID CHANNEL STRUCTURE OF NON-INVASIVE PROSTHETIC DEVICE | VIRK, ADIL PARTAP S | 3798 | §102§103§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18253857 | SYNTHESIS OF [18F]-LABELED THYMIDINE ANALOGUES | BAEK, JONGHWAN NMN | 1618 | §103DP | Final Rejection | 15d | Pending | May 22, 2023 |
| 18312194 | NANOPARTICLE VACCINES AND USES THEREOF FOR PROPHYLAXIS AND TREATMENT OF ATHEROSCLEROSIS USING PEPTIDE 210 AS AN ANTIGEN | ALLEN, MARIANNE P | 1647 | §103 | Non-Final OA | 71d | Pending | May 04, 2023 |
| 18184497 | ORGANIC PHOTOSENSITIVE DEVICES WITH EXCITON-BLOCKING CHARGE CARRIER FILTERS | CHERN, CHRISTINA | 1722 | §101 | Non-Final OA | 85d overdue | AI Ready | Mar 15, 2023 |
| 18097703 | POINT CLOUD CODING DEVICE, POINT CLOUD DECODING DEVICE, POINT CLOUD CODING METHOD, POINT CLOUD DECODING METHOD, AND PROGRAM | CHOI, TIMOTHY WING HO | 2671 | §103 | Final Rejection | — | Pending | Jan 17, 2023 |
| 18079714 | Endoscope with Pressure Recorder | STARKEY, OLIVIA GRACE | 3795 | §103§112 | Non-Final OA | — | Pending | Dec 12, 2022 |
| 17928690 | METHODS AND COMPOSITIONS FOR IN VITRO AFFINITY MATURATION OF MONOCLONAL ANTIBODIES | BUNKER, AMY M | 1684 | §103§112 | Final Rejection | 63d | Pending | Nov 30, 2022 |
| 17927454 | SCALABLE TRIO GUIDE RNA APPROACH FOR INTEGRATION OF LARGE DONOR DNA | SHEN, WU CHENG WINSTON | 1682 | §101§102§103§112 | Final Rejection | — | Pending | Nov 23, 2022 |
| 17996452 | CYCLODEXTRIN BASED ANTI-MICROBIAL THERAPY | CHO, DAVID H | 1693 | §103 | Non-Final OA | — | Pending | Oct 18, 2022 |
| 17948904 | Compositions and Methods for Treating Multidrug Resistant Bacterial Infection | KATAKAM, SUDHAKAR | 1658 | §103§112Other | Non-Final OA | — | Pending | Sep 20, 2022 |
| 17912313 | SCREENING METHODS TO IDENTIFY SMALL MOLECULE COMPOUNDS THAT PROMOTE OR INHIBIT THE GROWTH OF CIRCULATING TUMOR CELLS, AND USES THEREOF | SCHLIENTZ, LEAH H | 1618 | §103 | Final Rejection | — | Pending | Sep 16, 2022 |
| 17794920 | COMPOSITIONS AND METHODS TO TREAT NEUROLOGICAL DISEASES | GIBBS, TERRA C | 1635 | §103§112 | Non-Final OA | 72d | Pending | Jul 22, 2022 |
| 17786481 | UTILIZATION OF A FASTING-MIMICKING DIET TO REDUCE SENESCENT CELLS AND INFLAMMATION | O'HERN, BRENT T | 1793 | §112 | Final Rejection | 44d overdue | Pending | Jun 16, 2022 |
| 17642524 | ANALYSIS METHODS FOR MULTIPLEX TISSUE IMAGING INCLUDING IMAGING MASS CYTOMETRY DATA | WHALEY, PABLO S | 3619 | §101§103§112 | Non-Final OA | — | Pending | Mar 11, 2022 |
| 17691958 | MODULAR SYNTHON-BASED SCREENING APPROACH FOR USE IN DRUG DISCOVERY FOR DISEASES | PLAYER, ROBERT AUSTIN | 1686 | §101§103 | Final Rejection | — | Pending | Mar 10, 2022 |
| 17618240 | ENGINEERED OFF-THE-SHELF IMMUNE CELLS AND METHODS OF USE THEREOF | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §102 | Final Rejection | — | Pending | Dec 10, 2021 |
| 17541558 | FASTING MIMICKING KETOGENIC DIET (FMD) TO PROMOTE SKELETAL MUSCLE REGENERATION AND STRENGTH | MOSS, NATALIE M | 1653 | §103 | Final Rejection | 59d overdue | Pending | Dec 03, 2021 |
| 17399920 | CLASSIFICATION OF SUBTYPES OF KIDNEY TUMORS USING DNA METHYLATION | GOLDBERG, JEANINE ANNE | 1682 | §101§112 | Non-Final OA | 42d overdue | Pending | Aug 11, 2021 |
| 17176750 | FASTING MIMICKING AND ENHANCING DIET FOR TREATING HYPERTENSION AND LIPID DISORDERS | FISCHER, JOSEPH | 1658 | §112 | Final Rejection | — | Pending | Feb 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial